OncoMatch/Clinical Trials/NCT07210086
Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
Is NCT07210086 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including ADT and ARSI for prostate cancer.
Treatment: ADT · ARSI — This study aims to evaluate the role of PSMA-PET and circulating tumor DNA (ctDNA) in monitoring prostate cancer progression and response to radiotherapy (RT). Specifically, it investigates how often early progression is detected on PSMA-PET before PSA rise, examines PET responses of lesions treated with RT at 6 and 12 months and their correlation with PSA changes and later progression, examines ctDNA changes following ablative-intent RT to metastatic sites, and explores the relationship between PSMA-PET radiological findings and ctDNA dynamics.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
KPS OR ECOG 0–1
KPS ≥ 70 or ECOG 0-1
Demographics
Prior therapy
Cannot have received: androgen deprivation therapy
Exception: ≤ 3 months of neoadjuvant ADT prior to consent allowed
Any patient planning to receive lifelong continuous or intermittent ADT; For the current treatment course, patient must not have received more than 3 months of neoadjuvant ADT prior to consent.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07210086 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages